news

CUPERTINO, Calif., Nov. 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company has completed its first study in humans with its post-operative pain relief depot product. DURECT’s post-operative pain relief depot product, a sustained release injectable using the SABER delivery system and a local anesthetic, is designed to be administered locally around […]

CUPERTINO, Calif., Oct. 20 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, November 6, 2003 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has received data from a preclinical animal test with its CHRONOGESIC(R) (sufentanil) Pain Therapy Product which indicate that a small number of units (less than 2% in total) utilizing the new system design under evaluation by the Company experienced a premature

CUPERTINO, Calif., Oct 9, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated manufacture of clinical product for its anticipated pharmacokinetic study and other initial clinical studies in the Phase III program for its CHRONOGESIC(R) (sufentanil) Pain Therapy product using the Company’s new terminal sterilization manufacturing process. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO

CUPERTINO, Calif., Sept. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed Jon S. Saxe to its Board of Directors to replace James R. Butler who stepped down as a member of the Board of Directors in June 2003. Mr. Saxe will begin in his new capacity immediately. The appointment

CUPERTINO, Calif., Sep 3, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Thomas Weisel Partners Annual Healthcare Conference. The conference is being held at the Four Seasons Hotel in Boston, MA. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Friday,

CUPERTINO, Calif., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed validation of the terminal sterilization manufacturing process for its CHRONOGESIC (sufentanil) Pain Therapy product. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Our stated objectives this year were to implement some necessary design and manufacturing enhancements to our CHRONOGESIC product and

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill — 23rd Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Wednesday, August

CUPERTINO, Calif., Jul 24, 2003 /PRNewswire-FirstCall via Comtex/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2003. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended June 30, 2003 was $5.1 million or 10 cents per share, compared to $9.9 million or 21 cents per

CUPERTINO, Calif., Jul 11, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that the initial purchaser of $50 million of its 6.25% Convertible Notes due 2008 has elected to exercise its option to purchase an additional $10 million principal amount of such Notes. As a result, the final aggregate principal amount of